several studies point out the value of preoperative natriuretic peptides as independent risk predictors. 4 5 A recent systematic review and meta-analysis on preoperative BNP and NT-proBNP as predictors of adverse outcome after cardiac surgery revealed that there are still limited data available, and that studies differ considerably in sample size, inclusion criteria, endpoints, and quality. 6 It concluded that BNP and NT-proBNP have a moderate ability to predict short-and long-term mortality and morbidity. In a study on patients operated with CABG for acute coronary syndrome (ACS), we identified a cut-off value for preoperative NT-proBNP of 1028 ng litre 21 as a predictor of both postoperative severe circulatory failure and in-hospital mortality. 7 In that study, NT-proBNP≥1028 ng litre 21 emerged as an independent risk factor for severe circulatory failure after operation. Preoperative NT-proBNP≥1028 ng litre 21 was more pre-factor for severe circulatory failure after operation even after adjustment for EuroSCORE. 7 When designing the recently launched EuroSCORE II model, the relevance of natriuretic peptides as an independent factor in predicting cardiac surgical outcome was acknowledged. 8 However, this biochemical marker was not included in the risk calculation because the BNP data were too limited. Therefore, the primary aim of this study was to examine if preoperative NT-proBNP and our previously identified cut-off level of NT-proBNP≥1028 ng litre 21 could provide prognostic information in addition to EuroSCORE II in predicting severe circulatory failure after operation in patients with ACS undergoing isolated CABG.
Methods

Ethics approval
After written informed consent, the patients were enrolled in the study. The study was performed according to the Helsinki Declaration of Human Rights and was approved by the Swedish Medical Products Agency (151:2003/70403) and the Regional Ethical Review Board in Linköping (M76-05).
Patients
Between May 2007 and November 2009, we prospectively included 366 patients in a prespecified substudy of the GLUTA-MICS trial (ClinicalTrials.gov Identifier: NCT00489827). The trial was originally powered for 2214 patients with regard to the intervention but was terminated after interim analysis as prespecified stopping criteria per protocol were fulfilled. 9 For details regarding the GLUTAMICS trial, see Supplementary material. Patients were operated at three Swedish cardiac surgery centres (Linkö ping, Ö rebro, and Karlskrona). Inclusion criteria were patients operated with isolated CABG for ACS. Patients were eligible for inclusion regardless if the procedure was done on-pump (n¼354) or off-pump (n¼12). Exclusion criteria are presented in the Supplementary material.
Study design
An observational longitudinal study to evaluate EuroSCORE II and preoperative NT-proBNP for prediction of severe circulatory failure after operation in patients undergoing isolated CABG for ACS. Patients were included prospectively and based on our original database, we retrospectively calculated EuroSCORE II for each patient. Calculation was done with the EuroSCORE II interactive calculator at www.euroscore.org. One patient was excluded due to missing data for adequate EuroSCORE II calculation, leaving 365 patients for final analysis (Fig. 1) .
Sampling for NT-proBNP was done in the operating theatre immediately before induction of anaesthesia and plasma levels were analysed using electro-chemiluminescence immunoassay on a Roche Elecsys 2010 automated platform (Roche Diagnostics, Basel, Switzerland). The results of NTproBNP were released from the laboratory when the trial was terminated. (Fig. 1) .
Study endpoints
The primary endpoint was severe circulatory failure after operation during the first hospitalization. The secondary endpoints were in-hospital mortality and late mortality. Mortality was divided into cardiac or non-cardiac-related cause of death. Assessments were done according to prespecified criteria by an endpoints committee consisting of consultants in cardiothoracic anaesthesia and cardiothoracic surgery from the three centres participating in the study. The committee was blinded to the results of the NT-proBNP analyses. For details, see Supplementary material. Data on late mortality were retrieved from the Swedish Civil Registry and the cause for late mortality was retrieved from the Causes of Death Registry at the Swedish National Board of Health and Welfare.
Definitions
Severe circulatory failure was defined as circulatory failure leading to death or requiring stay in the intensive care unit (ICU) ≥48 h with intra-aortic balloon pump for ≥24 h or inotropic agents for ≥24 h in dosages described in the Supplementary material. In-hospital mortality was defined as mortality during the first hospitalization period including stay at the referral hospital after discharge from the cardiac surgical unit. Cardiac cause of death was defined as death caused by or initiated by a cardiac event such as heart failure or myocardial infarction.
Definitions for left ventricular failure at weaning from cardiopulmonary bypass (CPB), perioperative myocardial infarction, postoperative renal dysfunction, and stroke are given in the Supplementary material.
Peroperative management
Clinical management was standardized and similar at the three participating centres with minor differences concerning choice of anaesthetic drugs. Standard surgical techniques were used. Twelve patients were operated off-pump without aortic cross-clamping. In the other patients, standard use of CPB and aortic cross-clamping was used. Crystalloid or blood cardioplegia was used for myocardial protection. Intraoperatively, a surgical pulmonary artery catheter was introduced in all patients for measurement of mixed venous oxygen saturation and pressure as previously described. 11 For details on clinical management, see Supplementary material.
Statistics
Multivariable analysis of independent predictors for severe circulatory failure after operation was done with forward stepwise multiple logistic regression. The Hosmer-Lemeshow goodness-of-fit statistics were calculated for the final model. Variables with a P-value of ,0.25 in the univariable analysis were tested in the multivariable model. Receiver operating characteristics (ROC) analysis was carried out to calculate the area under the curve (AUC) and to evaluate discrimination of NT-proBNP and EuroSCORE II with regard to severe circulatory failure after operation. Multivariable logistic regression was used to build a model with EuroSCORE II and NT-proBNP after log transformation of both variables. Areas under ROC curves were compared using a non-parametric approach. 12 
Results
The mean age of the whole study population (n¼365) was 68 (9) yr and 19% were females. EuroSCORE II was 3.3 (2.7) (range 0.85 -20.2) with a median value of 2.4. The mean value of preoperative NT-proBNP was 889 (1637) ng litre
21
(range 10 -15 900 ng litre 21 ) with a median value of 420 ng litre 21 . Severe circulatory failure after operation developed in 1.9% (7/365). In-hospital mortality was 1.4% (5/365), 30 day mortality was 1.1% (4/365), and in-hospital plus 30 day mortality was 1.6% (6/365). Among the six patients with in-hospital or 30 day mortality, five died of cardiac causes and one due to gastrointestinal bleeding.
Predictive value of EuroSCORE II and NT-proBNP with regard to severe circulatory failure after operation Discrimination with regard to severe circulatory failure after operation was almost identical for EuroSCORE II and preoperative NT-proBNP (as a continuous variable) with an AUC of 0.87 for both variables (Table 1) . Discrimination did not improve significantly with the combined model of EuroSCORE II and preoperative NT-proBNP compared with EuroSCORE II alone (P¼0.14). The ROC curve for the combined model is shown in Figure 2 . Clinical outcome with regard to NT-proBNP above or below 1028 ng litre 21 in different risk categories according to EuroSCORE II An overview of the perioperative characteristics in patients stratified according to EuroSCORE II is presented in Table 2 .
Low-risk group: EuroSCORE II<2.0
The mean value of preoperative NT-proBNP was 421 (654) had significantly lower haemoglobin and higher plasmatroponin T (Table 3 ). The group with high NT-proBNP had significantly more inotropic support intraoperatively (36% vs 10%, P¼0.026) and on arrival in the ICU (36% vs 5.3%, P¼0.0047) ( Table 3) .
Intermediate-risk group: EuroSCORE II 2.0 -10.0
The mean value of preoperative NT-proBNP was 1030 (1650) 142 (13) 113 (13) 
. Also, patients with high NT-proBNP had significantly more left ventricular failure at weaning from bypass (11.5% vs 2.7%, P¼0.016) and more inotropic support intraoperatively (33% vs 13%, P¼0.0008) ( Table 3) . After operation, severe circulatory failure was only observed in patients with high preoperative NT-proBNP (6.6% vs 0%, P¼0.007). Patients with high NT-proBNP also had significantly more stroke (6.6% vs 0.7%, P¼0.027), renal failure (15% vs 5.4%, P¼0.026), and longer ICU stay [37 (35) vs 27 (38) h, P¼0.002]. In-hospital plus 30 day mortality (3.3% vs 0%, P¼0.08) and 1 yr mortality (4.9% n¼3, vs 0%, P¼0.024) was only observed in the high NT-proBNP group (Table 3) .
High-risk group: EuroSCORE II>10.0
The mean value of preoperative NT-proBNP was 3837 (4112) Table 2 .
Long-term follow-up
The follow-up time for the whole study population (n¼365) was 4.4 (0.7) yr (range 3.1-5.6 yr). Cause of death could be established in 37 out of 39 patients. Cumulative freedom from cardiac death according to Kaplan -Meier was significantly worse for those with NT-proBNP≥1028 ng litre 21 (P¼0.002) (Fig. 3) .
Discussion
EuroSCORE II provided excellent predictive value with regard to severe circulatory failure after operation and in-hospital mortality in patients undergoing CABG for ACSs. In spite of this, preoperative NT-proBNP≥1028 ng litre 21 emerged as an independent risk factor for developing severe circulatory failure even after adjusting for EuroSCORE II. NT-proBNP≥1028 ng litre 21 provided additional prognostic information regarding postoperative morbidity in patients considered to be at intermediate risk according to EuroSCORE II.
Complications to perioperative heart failure are the leading causes for adverse outcome after cardiac surgery. 1 13 Consequently, it is important to identify patients with increased risk for developing postoperative heart failure before operation.
Owing to the lack of generally accepted criteria for postoperative heart failure in association with cardiac surgery, a clinical endpoints committee relying on prespecified criteria was considered necessary in the study to get a robust evaluation on severe circulatory failure after operation. Natriuretic peptides are well-known markers for heart failure, and the prognostic value of preoperative NT-proBNP has been well documented in cardiac surgery. 4 -6 In a recent study on patients undergoing isolated CABG, we found a cut-off level for preoperative NT-proBNP of 1028 ng litre 21 to be independently predictive of severe circulatory failure after operation, according to strict prespecified criteria, even after adjustment for EuroSCORE. 7 This finding was in agreement with other cardiac surgical studies where natriuretic peptides measured before operation were independently predictive of postoperative outcome even when adjusted for EuroSCORE. 14 15 However, the recently launched EuroSCORE II has been recalibrated and includes some different predictors and introduces new classifications of already existing predictors. 8 It has been suggested that a combination of biomarkers and clinical assessment could prove the most useful means to determine preoperative risk in cardiac surgery. 4 However, natriuretic peptides were not included in the EuroSCORE II risk calculation as data were only available for a small proportion of the patients. In light of this, new evaluations of NT-proBNP in relation to EuroSCORE II are desirable. Multivariable analysis in the present study on patients undergoing isolated CABG for ACS support claims that NT-proBNP can provide additional prognostic information to EuroSCORE II. According to ROC analysis, the ability to recognize patients who developed severe circulatory failure after operation was excellent and almost identical for EuroSCORE II and preoperative NT-proBNP. Combining these variables improved AUC slightly but not significantly. However, the cut-off value for NT-proBNP≥1028 ng litre 21 emerged as an independent risk factor in the multivariable analysis in contrast to NT-proBNP as a continuous variable. For the ROC analyses, NT-proBNP was analysed as a continuous variable. EuroSCORE II was designed to predict in-hospital mortality, but in this study, it also demonstrated excellent predictive value for severe circulatory failure after operation. This could be explained by the major role of heart failure for postoperative mortality. Vice versa, this could explain the predictive value of NT-proBNP≥1028 ng litre 21 with regard to in-hospital mortality. We have previously reported that preoperative NT-proBNP was more predictive of severe circulatory problems after operation than echocardiographic assessment of left ventricular function. 7 NT-proBNP provides an objective measurement also taking diastolic dysfunction into account even in the absence of impaired systolic function assessed by echocardiography. 16 This does not necessarily imply that NT-proBNP should be evaluated for inclusion in risk models as it might be more useful as a complement to clinical assessment. To assess what clinical outcomes NT-proBNP≥1028 ng litre 21 might be associated with we stratified patients into three risk categories based on a recent evaluation of Euro-SCORE II. 10 The results of our study suggest that NT-proBNP can add information to EuroSCORE II in identifying patients who carry an increased risk of developing severe circulatory problems during the perioperative period. In the low-risk group with EuroSCORE II,2.0, there were few patients with high NT-proBNP. In spite of this, NT-proBNP provided prognostic information to EuroSCORE II regarding the use of intraoperative inotropic support. In the intermediate-risk group with EuroSCORE II 2.0-10.0, the additive value of NT-proBNP was more evident. Severe circulatory failure and serious adverse outcomes such as renal failure, stroke, and prolonged ICU stay were more common in patients with NT-proBNP≥1028 ng litre 21 . Owing to a limited number of events, the mortality difference did not reach statistical significance in-hospital or at 30 days, but was statistically significant at 1 yr.
In the high-risk group (EuroSCORE II .10.0), there were only two patients with NT-proBNP,1028 ng litre 21 and therefore, a statistical analysis was not performed in relation to NT-proBNP level.
Cumulative freedom from cardiac death according to Kaplan-Meier was significantly worse for patients with preoperative NT-proBNP≥1028 ng litre 21 . This finding supports a recent study that found increased perioperative BNP concentrations to be associated with hospitalization or death related to heart failure during the 5 yr after primary CABG. 17 Furthermore, in a non-selected group of cardiac surgery patients, it has been shown that preoperative NT-proBNP had moderate accuracy in predicting mortality at 3 yr. 18 Apart from identifying high-risk patients, it is also desirable to identify patients who can undergo open cardiac surgery with a lower risk than indicated by conventional risk scoring. A notable finding was that, regardless of EuroSCORE II, only one of the 282 patients with NT-proBNP,1028 ng litre 21 developed severe circulatory failure or died in hospital. This information could be particularly useful in high-risk patients with regard to operability and choice of procedure. Further studies are warranted to address this issue. The major limitation of this study is the retrospective calculation of EuroSCORE II in a relatively small sample size, but the study was prospective and unique in the sense that postoperative heart failure was determined by a blinded endpoints committee relying on strict prespecified criteria.
In conclusion, our results indicate that NT-proBNP provides additional prognostic information to EuroSCORE II in patients with ACS undergoing isolated CABG, particularly in those considered to be at intermediate risk.
Supplementary material
Supplementary material is available at British Journal of Anaesthesia online.
